Have a feature idea you'd love to see implemented?
Let us know!
HRTX Heron Therapeutics Inc
Price (delayed)
$1.58
Market cap
$240.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.16
Enterprise value
$392.81M
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron
Highlights
Heron Therapeutics's EPS has surged by 83% YoY and by 47% QoQ
HRTX's gross profit has surged by 81% year-on-year and by 11% since the previous quarter
The equity has declined by 44% year-on-year and by 5% since the previous quarter
The quick ratio has contracted by 9% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of HRTX
Market
Valuations
Earnings
Shares outstanding
152.09M
Market cap
$240.31M
Enterprise value
$392.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.85
Revenue
$137.74M
Gross profit
$99.43M
Net income
-$27.97M
EBIT
-$27.46M
EBITDA
-$24.84M
Free cash flow
-$9.6M
Per share
Balance sheet
Liquidity
EPS
-$0.16
EPS diluted
-$0.16
Free cash flow per share
-$0.06
Book value per share
-$0.26
Revenue per share
$0.9
TBVPS
$1.44
Total assets
$220.78M
Total liabilities
$260.78M
Debt
$178.25M
Equity
-$40.01M
Working capital
$109.64M
Debt to equity
-4.46
Current ratio
2.28
Quick ratio
1.61
Net debt/EBITDA
-6.14
Margins
Efficiency
Dividend
EBITDA margin
-18%
Gross margin
72.2%
Net margin
-20.3%
Operating margin
-18.8%
Return on assets
-12.7%
Return on equity
N/A
Return on invested capital
-9.3%
Return on capital employed
-20.3%
Return on sales
-19.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRTX stock price
How has the Heron Therapeutics stock price performed over time
Intraday
3.27%
1 week
-1.25%
1 month
41.07%
1 year
-2.47%
YTD
-7.06%
QTD
-20.6%
Financial performance
How have Heron Therapeutics's revenue and profit performed over time
Revenue
$137.74M
Gross profit
$99.43M
Operating income
-$25.92M
Net income
-$27.97M
Gross margin
72.2%
Net margin
-20.3%
HRTX's operating margin has surged by 81% year-on-year and by 45% since the previous quarter
HRTX's gross profit has surged by 81% year-on-year and by 11% since the previous quarter
The operating income has surged by 79% year-on-year and by 44% since the previous quarter
The net margin has soared by 79% year-on-year and by 42% since the previous quarter
Growth
What is Heron Therapeutics's growth rate over time
Valuation
What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.85
Heron Therapeutics's EPS has surged by 83% YoY and by 47% QoQ
The equity has declined by 44% year-on-year and by 5% since the previous quarter
HRTX's price to sales (P/S) is 78% less than its 5-year quarterly average of 7.9 and 38% less than its last 4 quarters average of 2.8
HRTX's revenue is up by 12% year-on-year
Efficiency
How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has surged by 79% YoY and by 43% QoQ
The ROIC has soared by 78% YoY and by 42% from the previous quarter
HRTX's ROA has soared by 76% YoY and by 41% QoQ
Dividends
What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRTX.
Financial health
How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 15% lower than its total liabilities
The quick ratio has contracted by 9% YoY and by 9% from the previous quarter
The current ratio has contracted by 6% YoY and by 4.2% from the previous quarter
The equity has declined by 44% year-on-year and by 5% since the previous quarter
The debt to equity is up by 31% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.